Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting
- Full Data Presented From The First-In-Human Study of Imcgp100 in Metastatic Melanoma, Treating 84 Patients
- Prolonged Responses Were Observed in Both Uveal and Cutaneous Melanoma
- Imcgp100 Showed a Favourable Safety Profile With Manageable Immune Mediated Toxicity
- The Data Presented Support Development in Uveal and Cutaneous Melanoma
Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, today announced that positive data from the first in human, Phase I clinical trial of its lead ImmTAC (Immune mobilising monoclonal TCRs Against Cancer), IMCgp100, was presented in a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 5th 2016.